



Date: April 16, 2026

**Valorum Biologics, LLC  
Notice Regarding Alymsys<sup>®</sup> NDC Changes  
National Drug Code Numbers Update and Impact on 340B Virtual Inventory Management**

Valorum Biologics, LLC has asked the Office of Pharmacy Affairs (OPA) to post this notice on the OPA's public website to notify 340B covered entities that the National Drug Code (NDC) numbers for Alymsys<sup>®</sup> (bevacizumab-maly) for intravenous infusion are being transitioned to new NDCs on July 1, 2026.

These NDC changes will be accompanied by the following product packaging changes: (1) identifying that the product is distributed by Valorum Biologics, LLC, (2) updated NDC numbers, (3) updated pharmacovigilance telephone number, and (4) inclusion of Valorum Biologics' logo.

Product Description	Old/Existing NDC	New/Replacement NDC	Effective Date
Alymsys (bevacizumab-maly) 100 mg/4 mL (25 mg/mL)	70121-1754-1	85006-1754-1	July 1, 2026
Alymsys (bevacizumab-maly) 400 mg/16 mL (25 mg/mL)	70121-1755-1	85006-1755-1	July 1, 2026

The new NDC(s) will not signify any change in product form, strength, or composition. Because each new Alymsys<sup>®</sup> NDC represents the same product as the corresponding old NDC, Valorum Biologics will permit eligible 340B covered entities that use a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities for each corresponding new NDC.

The new NDCs will be available as early as July 1, 2026. Amneal Pharmaceuticals will sell its remaining inventory of each old NDC until June 30, 2026, at which point Valorum Biologics will begin distributing the corresponding new NDC. Valorum Biologics or your distributor will communicate further information regarding the availability of each new NDC. Chargebacks and returns for the old NDCs will be processed by Amneal.

Any questions regarding this matter can be directed to [340BRelations@valorum.bio](mailto:340BRelations@valorum.bio).

Thank you.